Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.

Publication Type:
Journal Article
Future oncology (London, England), 2014, 10 (5), pp. 789 - 802
Issue Date:
Full metadata record
Files in This Item:
Filename Description Size
out (9).pdfPublished Version1.84 MB
Adobe PDF
Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia.
Please use this identifier to cite or link to this item: